We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

Back to rankings

149 hedge funds and large institutions have $327M invested in Achillion Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 55 increasing their positions, 32 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 12

72% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 32

59% more call options, than puts

Call options by funds: $983K | Put options by funds: $617K

19% more funds holding

Funds holding: 125 → 149 (+24)

32% less capital invested

Capital invested by funds: $480M → $327M (-$153M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
149
Holders Change
+24
Holders Change %
+19.2%
% of All Funds
3.38%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
36
Increased
55
Reduced
32
Closed
12
Calls
$983K
Puts
$617K
Net Calls
+$366K
Net Calls Change
-$365K

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$20.7M
2
Morgan Stanley
Morgan Stanley
New York
+$15.6M
3
EC
EcoR1 Capital
California
+$6.69M
4
BlackRock
BlackRock
New York
+$6.31M
5
BI
BVF Inc
California
+$5.84M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$47.4M
2
O
OrbiMed
New York
-$17.8M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$10.4M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$8.61M
5
AC
Armistice Capital
New York
-$4.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
26
Perceptive Advisors
New York
$2.88M +$3.63M +1,000,000 New
DCM
27
DAFNA Capital Management
California
$2.73M +$836K +230,000 +32%
ACH
28
ArrowMark Colorado Holdings
Colorado
$2.7M – – –
Norges Bank
29
Norges Bank
Norway
$2.47M – – –
EAM
30
Eventide Asset Management
Massachusetts
$2.45M – – –
SDIC
31
South Dakota Investment Council
South Dakota
$2.4M -$41.8K -11,500 -1%
AG
32
Artal Group
Luxembourg
$2.16M -$908K -250,000 -25%
Citadel Advisors
33
Citadel Advisors
Florida
$2.12M +$2.3M +633,626 +627%
SIM
34
Spark Investment Management
New York
$2.02M +$1.54M +422,800 +152%
RPAM
35
Rhenman & Partners Asset Management
Sweden
$1.92M -$662K -182,200 -21%
TCM
36
Tekla Capital Management
Massachusetts
$1.77M – – –
Bank of New York Mellon
37
Bank of New York Mellon
New York
$1.69M -$63.5K -17,474 -3%
RCM
38
RA Capital Management
Massachusetts
$1.69M -$47.4M -13,047,330 -96%
MWNA
39
Marshall Wace North America
New York
$1.61M +$2.03M +558,105 New
Charles Schwab
40
Charles Schwab
California
$1.58M +$85.7K +23,577 +4%
EU
41
Emory University
Georgia
$1.49M +$655K +180,360 +53%
QI
42
QS Investors
New York
$1.38M -$68.9K -18,972 -4%
PAM
43
Panagora Asset Management
Massachusetts
$1.32M +$1.55M +427,271 +1,404%
Bank of America
44
Bank of America
North Carolina
$1.27M +$138K +37,991 +9%
OM
45
Opaleye Management
Massachusetts
$1.27M +$1.6M +440,000 New
CS
46
Candriam SCA
Luxembourg
$1.25M -$18.2K -5,000 -1%
Stifel Financial
47
Stifel Financial
Missouri
$1.16M – – –
OAM
48
Oxford Asset Management
United Kingdom
$1.07M +$1.22M +335,529 +1,238%
D.E. Shaw & Co
49
D.E. Shaw & Co
New York
$1.06M +$1.26M +346,870 +1,706%
TCIM
50
TIAA CREF Investment Management
New York
$1.05M +$154K +42,358 +13%
1
2
3 4 5

ACHN Hedge Fund Activity: Q4 2017 in Review

149 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q4 2017, worth a combined $327M — down 32% from $480M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new ACHN positions and 12 closed out — a net gain of 24 holders — while 55 added to existing stakes and 32 trimmed.

The largest buyer was RTW Investments, adding an estimated $20.7M. The largest seller was RA Capital Management, cutting an estimated $47.4M.

  • 149 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q4 2017, up from 125 in Q3 2017.
  • Funds reported $327M of Achillion Pharmaceuticals stock for Q4 2017, down 32% quarter-over-quarter.
  • 36 funds opened new Achillion Pharmaceuticals positions in Q4 2017 and 12 closed out, a net change of +24 holders.
  • The largest Achillion Pharmaceuticals buyer in Q4 2017 was RTW Investments, an estimated $20.7M added.
  • The largest Achillion Pharmaceuticals seller in Q4 2017 was RA Capital Management, an estimated $47.4M sold.

Based on aggregated 13F filings for Q4 2017.